Who is sponsoring NCT03601312?

NCT03601312 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03601312?

Interventions in NCT03601312: Exposure and Response Prevention, OC-Go.

What condition does NCT03601312 study?

NCT03601312 studies Obsessive-Compulsive Disorder.

Is NCT03601312 still recruiting?

NCT03601312 is currently completed. Last updated 11 April 2022.

Last reviewed 2022-04-11 · How we verify

NCT03601312: OC-GoPhaseII

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Controlled Trial of Standard ERP and OC-Go

Completed NA Last updated 11 April 2022

What this trial tests

NA trial testing Exposure and Response Prevention in Obsessive-Compulsive Disorder in 27 participants. Completed in 11 August 2021.

Timeline

1 November 2018

Primary endpoint
18 June 2021

11 August 2021

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	27
Start date	1 November 2018
Primary completion	18 June 2021
Estimated completion	11 August 2021
Sites	1 location across United States

Drugs / interventions tested

Exposure and Response Prevention
OC-Go

Conditions studied

Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →

Sponsor

University of California, Los Angeles

Who can join

Adults 9 to 17, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase II of this study will examine the efficacy of the OC-Go application via a randomized controlled trial comparing standard exposure and response prevention (ERP) treatment for pediatric obsessive compulsive disorder (OCD) to exposure/response prevention (ERP) augmented with OC-Go. A cross-over design will be implemented for these 12 sessions of treatment, in which participants that were randomized to standard ERP will receive OC-Go augmented ERP for the second half of treatment, and vice versa. Efficacy will be investigated in a sample of 32 children with OCD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Exposure and Response Prevention

Trials testing the same drug.

NCT07011901 — Precision Analytic Research Methods in OCD · NA · recruiting
NCT05240924 — ERP to Improve Functioning in Veterans With OCD · NA · recruiting
NCT03747835 — Meal-Based Exposure and Response Prevention in Anorexia Nervosa · NA · completed

Other recruiting trials for Obsessive-Compulsive Disorder

Currently open trials in the same condition.

NCT06575075 — Pilot Study of RR-HNK in OCD · Phase 1, PHASE2 · recruiting
NCT05783817 — MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) · Phase 2 · recruiting
NCT07065669 — Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation · NA · recruiting
NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
NCT07000812 — EEG Evaluation of CBT for Obsessive-Compulsive Disorder · NA · active not recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03601312 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 11 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03601312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing